In GLP-1 and incretin-based medication trials, gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal discomfort are commonly monitored, along with more serious potential risks such as dehydration, gallbladder problems, pancreatitis, kidney-related complications in the setting of fluid loss, and heart-rate changes
Ann Pharmacother 48(5):562570
In several organ systems, at least part of the benefit appears to occur before major weight loss or independent of the number on the scale
And then for a snack, I might do cottage cheese or I might do some yogurt and sometimes even add more protein powder to that
The Role of Personalized Medical Supervision Because every individuals health history is unique, a one size fits all approach to weight loss is rarely safe or effective for those on multiple medications
~3.33mg/mL each of TB-500, KPV, GHK-Cu)